FYARRO
Sirolimus
- Strength
- 5 mg/mL
- Form
- Injection, Powder, Lyophilized, For Suspension
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
Aadi Bioscience, Inc.
SIROLIMUS
Listed by Camber Pharmaceuticals, Inc.
- Strength
- 1 mg/mL
- Form
- Solution
- Route
- Oral
- Class
- Kinase Inhibitor; mTOR Inhibitor Immunosuppre…
What it contains
- Sirolimus 1 mg/mL
FDA record
| Dosage form | Solution |
|---|---|
| Route | Oral |
| Drug class | Kinase Inhibitor; mTOR Inhibitor Immunosuppressant |
| Approval route | ANDA — approved generic |
| NDC code | 31722-316 |
| FDA application | ANDA215080 |
| RxNorm concept | 314230 |
| Package sizes listed | 1 |
| Marketed since | September 2024 |
Other products containing Sirolimus
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
HYFTOR
sirolimus
- Strength
- 2 mg/g
- Form
- Gel
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
Nobelpharma America, LLC
Sirolimus
- Strength
- 1 mg/1
- Form
- Tablet
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
Dr. Reddy's Laboratories Limited
Sirolimus
- Strength
- .5 mg/1
- Form
- Tablet
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
REMEDYREPACK INC.
sirolimus
- Strength
- .5 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
REMEDYREPACK INC.
Sirolimus
- Strength
- 1 mg/mL
- Form
- Solution
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
Rising Pharma Holdings, Inc.
Sirolimus
- Strength
- 1 mg/mL
- Form
- Solution
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
Mylan Pharmaceuticals Inc.
sirolimus
- Strength
- .5 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
Zydus Lifesciences Limited
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.